Production (Stage)
Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.09
-$0.15-12.10%
OTC PK
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.75% | 15.56% | 9.26% | 9.26% | 10.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.75% | 15.56% | 9.26% | 9.26% | 10.56% |
| Cost of Revenue | -6.55% | 6.57% | 0.74% | 0.74% | -0.64% |
| Gross Profit | -16.05% | 21.57% | 14.71% | 14.71% | 17.61% |
| SG&A Expenses | -20.26% | 31.46% | 11.34% | 11.34% | 14.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 46.27% | -113.65% | 87.10% | 87.10% | 95.92% |
| Total Operating Expenses | -14.26% | 12.88% | 7.61% | 7.61% | 8.93% |
| Operating Income | -6.87% | 27.52% | 15.88% | 15.88% | 17.37% |
| Income Before Tax | 1.00% | 392.92% | 50.48% | 50.48% | 29.26% |
| Income Tax Expenses | 16.12% | -10.30% | 37.58% | 37.58% | 19.67% |
| Earnings from Continuing Operations | -4.08% | 710.04% | 55.35% | 55.35% | 32.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.39% | 710.04% | 55.35% | 55.35% | 14.39% |
| EBIT | -6.87% | 27.52% | 15.88% | 15.88% | 17.37% |
| EBITDA | -7.21% | 36.08% | 14.87% | 14.87% | 19.49% |
| EPS Basic | 5.93% | 683.78% | 60.08% | 60.08% | 19.19% |
| Normalized Basic EPS | -3.95% | 332.56% | 55.02% | 55.02% | 34.12% |
| EPS Diluted | 5.93% | 683.78% | 60.08% | 60.08% | 19.19% |
| Normalized Diluted EPS | -3.95% | 332.56% | 55.02% | 55.02% | 34.12% |
| Average Basic Shares Outstanding | 5.12% | 4.93% | -2.88% | -2.88% | -3.86% |
| Average Diluted Shares Outstanding | 5.12% | 4.93% | -2.88% | -2.88% | -3.86% |
| Dividend Per Share | -- | 166.96% | -- | -- | 12.38% |
| Payout Ratio | -0.24% | 1.14% | -0.29% | -0.29% | -- |